TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Enters into $6M Securities Purchase Agreement

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development and manufacturing of rare cannabinoids, has announced a private placement agreement with two healthcare-focused institutional investors. The agreement calls for the issuance and sale of 691,245 of INM common shares; the shares will be sold at a purchase price of $8.68 per share in a private placement priced according to Nasdaq guidelines. According to the announcement, InMed will also issue unregistered preferred investment options that will allow investors in the offering to purchase more than 1.3 million common shares. The company noted that it anticipates gross proceeds from the placement, which is expected to close on or about Sept. 13, 2022, to reach some $6 million. The company plans to use the funds gathered from the offering to continue its focus on pipeline development of its proprietary pharmaceutical drug candidates as well as advance manufacturing knowledge of cannabinoids and cannabinoid analogs and support intellectual property development and other commercial activities; the company may also use proceeds from the offering for general working capital purposes. The announcement also noted that any unregistered investment options issued in the offering will be exercisable upon issuance at an exercise price of $8.44 per share; the shares will expire seven years from the date of issuance.

To view the full press release, visit https://ibn.fm/zsfQD

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals is a global leader in the research, development and manufacturing of rare cannabinoids, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs.  We also have significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors. For more information, please visit www.InMedPharma.com.  

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM

About TinyGems

TinyGems is your guide to the best and brightest in the under-appreciated small-cap sector. As one of 50+ brands within the InvestorBrandNetwork (“IBN”), TinyGems provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to reach millions of social media followers; and (5) a full array of corporate communications solutions. It’s time to uncover some of the best-kept secrets on Wall Street. TinyGems features innovative small-cap companies with huge potential, putting a spotlight on the best and brightest of these disruptors that have the technology, the talent, the drive, and the business models to make a huge impact in the markets and in portfolios. Whether it’s a game changing technology, a new more profitable product or service, or a star in a hot sector, TinyGems is the go-to source for actionable intelligence.

To receive SMS text alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.com
310.299.1717 Office
Editor@TinyGems.com

TinyGems is part of the InvestorBrandNetwork

Alex Pearon

Share
Published by
Alex Pearon

Recent Posts

TinyGemsBreaks – NextPlat Corp (NASDAQ: NXPL) Issues CEO Update, Reaffirms Commitment to Growth Following Leadership Transition

NextPlat (NASDAQ: NXPL, NXPLW) released a shareholder letter from Interim CEO expressing confidence in the…

1 week ago

TinyGemsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Highlights 2025 Pipeline Progress and Strategic Focus in Shareholder Letter

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotech company developing systemic oncolytic targeted immunotherapies, released…

2 weeks ago

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights GBM Treatment Insights in KOL Segment Featuring Dr. Erin Dunbar 

CNS Pharmaceuticals (NASDAQ: CNSP) announced the release of a Virtual Investor KOL Connect segment featuring…

2 weeks ago

TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Positive Preclinical Results for INM-901 in Alzheimer’s Neuroinflammation Model 

InMed Pharmaceuticals (NASDAQ: INM), a pharmaceutical company developing small molecule drug candidates for diseases with…

2 weeks ago

TinyGemsBreaks – Vision Marine Technologies Inc. (NASDAQ: VMAR) Acquires Nautical Ventures to Launch First Integrated Electric Boat Dealership in North America

Vision Marine Technologies (NASDAQ: VMAR), a leader in high-voltage electric marine propulsion, has acquired Nautical…

2 weeks ago

TinyGemsBreaks – D-Wave Quantum Inc. (NYSE: QBTS) Signs MOU to Advance Quantum Computing in South Korea

D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software, and services, announced…

3 weeks ago